Table 1. Baseline Characteristics of Patients Who Were NE and LTFU.
| Total (n=1083) | NE (n=353) | LTFU (n=730) | p value | ||
|---|---|---|---|---|---|
| Age (yr) | 48.5±16.0 | 50.5±16.3 | 47.5±15.8 | <0.001 | |
| Age group | 0.003 | ||||
| ≤24 years | 70 (6.5) | 15 (4.3) | 55 (7.5) | ||
| 25–34 years | 158 (14.6) | 44 (12.5) | 114 (15.6) | ||
| 35–44 years | 215 (19.9) | 74 (21.0) | 141 (19.3) | ||
| 45–54 years | 287 (26.5) | 85 (24.1) | 202 (22.7) | ||
| 55–64 years | 176 (16.3) | 56 (15.9) | 120 (16.4) | ||
| 65–74 years | 88 (8.1) | 42 (11.9) | 46 (6.3) | ||
| ≥75 years | 89 (8.2) | 37 (10.5) | 52 (7.1) | ||
| Gender | 0.007 | ||||
| Female | 261 (34.1) | 103 (29.2) | 158 (21.6) | ||
| Male | 822 (75.9) | 250 (70.8) | 572 (78.4) | ||
| Resident region | 0.002 | ||||
| Metropolitan | 538 (49.7) | 151 (42.8) | 387 (53.0) | ||
| Others | 545 (50.3) | 202 (57.2) | 343 (47.0) | ||
| Nationality | <0.001 | ||||
| Korean | 929 (85.8) | 326 (92.4) | 603 (82.6) | ||
| Immigrant | 154 (14.2) | 27 (7.7) | 127 (17.4) | ||
| Household incomes | 0.001 | ||||
| 0 (lowest) | 162 (15.0) | 53 (15.0) | 109 (14.9) | ||
| 1 | 216 (19.9) | 64 (18.1) | 152 (20.8) | ||
| 2 | 243 (22.4) | 60 (17.0) | 183 (25.1) | ||
| 3 | 220 (20.3) | 71 (20.1) | 149 (20.4) | ||
| 4 | 135 (12.5) | 59 (16.7) | 76 (10.4) | ||
| 5 (highest) | 107 (9.9) | 46 (13.0) | 61 (8.4) | ||
| Treatment history | 0.089 | ||||
| New | 491 (45.3) | 147 (41.6) | 344 (47.1) | ||
| Previously treated | 592 (54.7) | 206 (58.4) | 386 (52.9) | ||
| Lesion site | 0.090 | ||||
| Pulmonary | 1063 (98.2) | 350 (99.2) | 713 (97.7) | ||
| Extra-pulmonary | 20 (1.8) | 3 (0.9) | 17 (2.3) | ||
| Notifying institution 1 | 0.923 | ||||
| PPM | 315 (29.1) | 102 (28.9) | 213 (29.2) | ||
| Non-PPM | 768 (70.9) | 251 (71.1) | 517 (70.8) | ||
| Notifying institution 2 | 0.172 | ||||
| Health center | 115 (10.6) | 31 (8.8) | 84 (11.5) | ||
| Private institution | 968 (89.4) | 322 (91.2) | 646 (88.5) | ||
| Smear | 0.507 | ||||
| Positive | 591 (54.6) | 184 (52.1) | 407 (55.8) | ||
| Negative | 431 (39.8) | 147 (41.6) | 284 (38.9) | ||
| ND/unknown | 61 (5.6) | 22 (6.2) | 39 (5.3) | ||
| Culture | <0.001 | ||||
| Positive | 737 (68.1) | 213 (60.3) | 524 (71.8) | ||
| Negative | 120 (11.1) | 43 (12.2) | 77 (10.6) | ||
| ND/unknown | 226 (20.9) | 97 (27.5) | 129 (17.7) | ||
| Resistance pattern | <0.001 | ||||
| RR | 75 (6.9) | 17 (4.8) | 58 (8.0) | ||
| MDR | 816 (75.3) | 240 (68.0) | 576 (78.9) | ||
| Pre-XDR (SLID) | 22 (2.0) | 2 (0.6) | 20 (2.7) | ||
| Pre-XDR (FQ) | 43 (4.0) | 20 (5.7) | 23 (3.2) | ||
| XDR | 127 (11.7) | 74 (21.0) | 53 (7.3) | ||
| Comorbidity | |||||
| Diabetes mellitus | 217 (20.0) | 81 (23.0) | 136 (18.6) | 0.096 | |
| Cancer | 19 (1.8) | 5 (1.4) | 14 (1.9) | 0.556 | |
| Time to outcome (days) | 274 [106–471] | 99 [13–227] | 319 [188–518] | <0.001 | |
NE, not evaluated; LTFU, lost to follow-up; PPM, public-private mix; ND, not done; RR, rifampin resistance; MDR, multidrug resistance; SLID, second-line injectable drug; FQ, fluoroquinolone; XDR, extensively drug-resistant; IQR, interquartile range.
Data are presented as mean±standard deviation, n (%), or median [IQR].